Advanced-Stage Primary Cutaneous T-Cell Lymphoma Treated with Bexarotene and Denileukin Diftitox
| Autor: | Luis Miguel Torres-Iglesias, I. Cervigón-González, Braulio Gil-Pascual, A. Palomo-Arellano |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Mycosis fungoides
Oncology medicine.medical_specialty Cutaneous T-cell lymphoma medicine.medical_treatment Dermatology Denileukin diftitox Internal medicine lcsh:Dermatology medicine Bexarotene Chemotherapy business.industry lcsh:RL1-803 medicine.disease Primary cutaneous T-cell lymphoma Lymphoma Published: February 2011 Leukemia business medicine.drug |
| Zdroj: | Case Reports in Dermatology, Vol 3, Iss 1, Pp 13-17 (2011) Case Reports in Dermatology |
| ISSN: | 1662-6567 |
| Popis: | Advanced-stage primary cutaneous T-cell lymphoma has an unfavorable prognosis and low survival rates. Aggressive treatment with chemotherapy is not curative and causes considerable side effects. The combination of bexarotene and denileukin diftitox is associated with an acceptable safety profile and a likely synergistic effect because bexarotene is capable of modulating expression of IL-2 receptor and enhance the susceptibility of T-cell leukemia cells to denileukin diftitox. In the case reported here, the response to this combined treatment was satisfactory and well tolerated. The patient showed a complete regression of pruritus, restlessness, and insomnia. Skin lesions improved partially, and lymphadenopathy was reduced and finally disappeared completely. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|